trending

Healius Limited announced its 1HFY23 results

Feb 27, 2023

Healius Limited (ASX: HLS) announced its financial results for 1HFY23 as follows:

  • Base pathology revenue grew by 1% compared to 1HFY20, and revenue per ACC grew by 8% with footprint optimisation and growth in commercial revenue.
  • A cash flow conversion rate in excess of 100% was delivered with alignment between operating revenue and cash flow.
  • The company reaffirmed its bank gearing ratio at 2.98x at the end of FY23 and intended to continue within its covenants.
  • Taking into consideration its short-term gearing levels and cash conservation, the company has determined not to pay an interim dividend for 1HFY23.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com

By submitting your details and clicking on the button above, you agree to our Terms and Conditions, Privacy Policy and consent to receive marketing offers including to be contacted by email or phone. Before continuing, please read the Financial Services Guide available here.

Recent News

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions

Allow cookies